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Introduction
The 9th International Meeting on Neuroacanthocytosis Syndromes
was held on March 23th–25th, 2018 in Dresden, Germany. The
conference followed the tradition of the previous eight international
symposia, the last of which was held in Ann Arbor, USA in May, 2016.
Following the positive response to the previous meeting, a major
component of this year’s symposium was the participation of patients,
their families, and caregivers. The conference focused primarily on
chorea-acanthocytosis as one of the ‘‘core’’ diseases of neuroacantho-
cytosis syndromes, with some discussion also of McLeod syndrome.
These neurodegenerative diseases lead to chorea, epilepsy, cognitive
and behavioral problems, and acanthocytosis of red blood cells. While
chorea-acanthocytosis is caused by mutations in the VPS13A gene,
other ‘‘VPS13opathies’’ (VPS13B-D) were also topic of the meeting.
At present there are no treatments that can halt or slow down the
progression of these diseases. However, two pathways seem to be
prominently involved in chorea-acanthocytosis – namely the PI3K
(phosphoinositide 3-kinase) pathway and the Lyn kinase pathway –
both of which are potential ‘‘druggable’’ targets. Model organisms
including Dictyostelium, Drosophila, yeast, and mice, and human cell
models were presented. Finally, clinical translation and clinical trial
readiness in such a rare disease were extensively discussed.
The VPS13 Gene Family
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Clues to VPS13A Function from Clinical Observation?
A. Danek
Neurologische Klinik, Ludwig-Maximilians-Universita¨t, Munich, Germany
Chorea-acanthocytosis (ChAc) has become increasingly well char-
acterized clinically since VPS13A mutations were discovered as
its genetic basis in 2001. In spite of the wealth of in vivo and in
vitro models presented at neuroacanthocytosis symposia past and
present, its function (or functions) has so far remained elusive.
It may be worthwhile to review features of the disease for clues.
1) ChAc is an autosomal-recessive condition. 2) Gender distribution
appears equal. 3) In the great majority of patients, the VPS13A
product, chorein, is absent. 4) Disease manifestation typically occurs in
the third decade. 5) ChAc affects multiple organ systems, most
importantly the central and the peripheral nervous system. 6) There
is progressive nerve cell loss yet a relative increase in glia cells,
with brain atrophy as the final outcome. No intracellular inclusions
whatsoever, the supposed hallmark of neurodegeneration, have yet
been discovered, or extracellular protein aggregates. 7) CK elevation
occurs in probably all patients and clinical myopathy may be
observed. 8) Acanthocytosis is found often and points to involvement
of hemopoietic cells, but is not obligatory. 9) Connections with other
so-called neuroacanthocytosis syndromes appear tenuous, apart from
McLeod syndrome (MLS), which may be viewed as a more slowly
progressing, X-linked variant of the disease process (mostly in males),
with much delayed onset. 10) The involvement of VPS13B in
hemopoiesis as well as of VPS13C and VPS13D in neurodegenera-
tion is notable.
VPS13A function appears to be essential for neurons with their high
metabolic activity, and the mere lack of chorein seems sufficient to
explain ChAc. The absence of debris also speaks against ‘‘toxic gain
of function’’. Interestingly, about 2% of all currently known cases
diagnosed via DNA analysis have a normal chorein western blot:
it may be assumed that the underlying point mutations hit a region of
the protein with subsequent ‘‘loss of function’’.
Alternative pathways may temporarily compensate before wide-
spread cell loss, mainly of basal ganglia neurons, becomes
apparent. The many similarities between ChAc and MLS make
the protein affected in the latter, Kx, a natural candidate to
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provide such compensation. Additional compensatory pathways
may become known from current studies in disease models such as
yeast. Nevertheless, plasticity of the brain as a whole and/or differ-
ences in the time course of specific nerve cell subpopulations, not
necessarily ‘‘metabolic detours within cells’’, might explain delays
in age of onset. Also, while in MLS heart involvement is typical,
in ChAc it is a very rare exception.
With respect to the hemopoietic system, VPS13A mutations do not
appear to be of crucial importance. The presence of acanthocytes, with
wide ranges reported, seems unrelated to red cell function or survival,
yet no systematic data are available, e.g., on erythrocyte life span in
ChAc. Other rapidly dividing cell populations, such as those of the GI
tract, do not seem essentially affected either. So far, no data are
available on acanthocytosis or CK elevation in children with ChAc
mutations that may help to understand very early disease stages.
Muscle cell affection in ChAc seems more similar to hemopoietic than
to nervous system involvement.
Another open question relates to the issue of subclinical manifestations
in the parents of ChAc patients. A few reports mention acanthocytosis
in these carriers of a single gene copy mutation, yet all reports that
initially favored autosomal-dominant disease transmission were even-
tually disproven.
Concerning VPS13A function, currently the rare situations of point
mutations despite apparently normal chorein expression seem of
greatest clinical interest. Further, similarity/dissimilarity across the
range of disease manifestations of VPS13 gene family members needs
to be better characterized.




Wellcome Centre for Human Genetics, University of Oxford, Oxford, UK
Research on chorea-acanthocytosis (ChAc), an adult-onset rare neuro-
degenerative disorder, has been ongoing for 50 years. It started in
1968, when two families from New England and Kentucky (USA),
with several members affected by a neurological disease with acan-
thocytosis, were independently reported by Irvine Levine and Edmunt
Critchley, respectively, after whom this new condition was named the
Levine–Critchley syndrome. Other similar cases were reported later,
many of them under the generic denomination of neuroacanthocytosis.
This, however, is an umbrella term that includes several other similar
conditions, which contributed to create confusion in the field that was
only resolved by the identification of the genetic causes. For ChAc, this
was achieved about 30 years after the original case reports, when
the ChAc gene on chromosome 9q21 was described, allowing confir-
mation of the recessive nature of the disorder. This gene was later
renamed VPS13A because of its similarity to the yeast VPS13 gene,
and was identified as a member of a family containing four genes
(VPS13A, B, C, D), all of which have now been associated with
recessive disorders.
The identification of the genetic basis of ChAc has allowed us to
undoubtedly demonstrate that the disorder described by Critchley in
1968 was indeed ChAc, after a fortunate turn of events involving
a member of the original reported family getting in contact with a
member of the rather small ChAc scientific community. The same,
however, cannot be said about the condition described by Levine,
since genetic analysis of his original family has not yet been possible.
Extensive screening for pathogenic mutations in affected patients
revealed that ChAc results from a loss of function of chorein, the
protein encoded by the ChAc/VPS13A gene. These mutations have
a gene-wide distribution, with no hotspots, and include an extensive
range of mutations: large deletions, splicing-site mutations, small
insertion/deletions, nonsense mutations, or missense mutations. These
analyses provide important insights into the function of chorein. First,
the C-terminal region of the protein is essential for, at least, its ChAc-
related function(s) since patients with mutations in the last exons of the
VPS13A gene, resulting not in the absence but in the production of
mutant chorein altered only at the C-terminus, present the typical
symptomatology of the disorder. Second, only a reduced number
of missense changes have been described as pathogenic mutations,
suggesting that the specific individual residues modified in these cases
might be particularly relevant for some of the functions of chorein.
In any case, the overwhelming majority of described pathogenic ChAc
mutations led to absence of the protein, either by a mechanism
involving the degradation of the mutated RNA or by instability and
degradation of the mutant protein. This fact allowed us to develop a
semi-diagnostic test based on analysis of protein extracts from blood by
western blotting, which is a much faster and cheaper approach than
DNA sequencing. Most, although not all, ChAc cases would be
detected in this way, implying that the positive cases detected by
this test do not require further analysis unless a particular interest in
knowing the causative mutations exists.
Finally, there has been debate over the existence of ‘‘dominant ChAc’’,
that is, the description of patients presenting with ChAc syndrome
but having only one mutated VPS13A allele while the second one is
normal. This would imply the single mutation present in these cases
has a dominant nature, and that its mere presence in an individual
would lead to development of ChAc. This was not only a question of
scientific debate but also a cause of deep worry for patients and
families that the possibility that carriers of VPS13A mutations (such
as children of ChAc patients) could indeed develop the disease. This
debate, however, seems to have been settled by the demonstration that
some of the cases initially reported as ‘‘dominant’’ had indeed muta-
tions in both VPS13A alleles, but one had been missed in the initial
report. While theoretically it is possible that a mutation in the VPS13A
gene has a dominant effect leading to ChAc, it is important to note that
such a mutation has not been described so far, and that ChAc is only
developed when both VPS13A alleles present pathogenic mutations.
Copyright: ’ 2018 Velayos-Baeza
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Cohen syndrome is an autosomal recessive disorder caused by muta-
tions in the gene VPS13B (COH1). Prominent clinical features are
intellectual disability, postnatal microcephaly, pigmentary retinopathy,
and intermittent neutropenia. We identified the encoded VPS13B
(3,997 aa), as a peripheral scaffold protein that localizes to the Golgi
complex and contributes to its structural maintenance and function.
Another study showed that disturbed Golgi complex homeostasis
affects glycan maturation and that VPS13B-deficient cells display
a reduced quantity of early endosomes and abnormally enlarged
lysosomes, pointing to a role of VPS13B in endosomal–lysosomal
trafficking. We show that RNAi-mediated knockdown of the small
GTPase RAB6A/A9, which tethers vesicles to the Golgi membrane
and controls several trafficking steps, prevents Golgi localization of
VPS13B. Co-immunoprecipitation experiments and mass spectrum
analyzes confirmed the physical interaction of VPS13B with RAB6,
which is in line with studies on yeast Vps13p. Our ongoing work
focuses on Vps13b expression analyses, identification of other VPS13B
interactors similar to the known yeast Vps13p network, and cortical
development studies using RNAi. Depletion of VPS13B in primary
neurons from the cortex negatively interferes with neurite outgrowth,
indicating a causal link between the integrity of the Golgi complex and
abnormal intracellular trafficking. Using in utero electroporation of
shRNA, we induced a selective neuronal Vps13b knockdown in mice
at different developmental stages. Initial data demonstrate that Golgi
orientation and neuronal migration are affected.
Together, we conclude that VPS13B is a RAB6 effector protein,
and that reduced brain size in patients with Cohen syndrome likely
results from impaired VPS13B function at the Golgi complex causing
decreased neuritogenesis and subsequently altered neuronal migration.
Copyright: ’ 2018 Lommatzsch et al.
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Genetic Contribution of Mutated VPS13C to Lewy Body
Dementia
C. Van Broeckhoven, S. Smolders, S. Van Mossevelde, S. Philtjens
Neurodegenerative Brain Diseases, Center for Molecular Neurology, VIB & Labo-
ratory of Neurogenetics, Institute Born-Bunge, University of Antwerp, Antwerp,
Belgium
VPS13C was first identified as a novel risk gene for Parkinson’s disease
(PD) in a genome-wide association meta-analysis for Parkinson’s
disease.1 Homozygous or compound heterozygous truncating muta-
tions in VPS13C were associated with a distinctive phenotype of rapid
and severe progression, suggesting that loss of function of VPS13C
is a cause of autosomal recessive early-onset PD.2 Diagnostic exome
sequencing in 80 patients with PD symptoms at early age and a
negative family history identified compound heterozygous variants in
one patient affecting canonical splice sites in VPS13C, confirming the
causal role of protein-truncating variants to autosomal-recessive early-
onset PD.3
In our study, we identified compound heterozygous, non-synonymous
variants that reduced VPS13C expression and were associated with
Lewy body disease (LBD). LBD is the second most prevalent cause
of neurodegenerative dementia, with a frequency of 10–25%. Com-
pound heterozygous missense mutations were identified by whole-
genome sequencing in an affected sib pair with early-onset dementia.
The index patient was pathologically diagnosed with LBD and the
parents were not affected. Screening of VPS13C in a Belgian LBD
cohort resulted in the identification of two additional carriers of com-
pound heterozygous VPS13C missense mutations, a pathologically
confirmed LBD patient and a clinically diagnosed LBD patient. In
patient-derived lymphoblast cells, the presence of the two mutant
alleles decreased endogenous VPS13C protein expression by almost
90%. Expression of VPS13C in brains at autopsy of the two LBD
carriers of compound heterozygous VPS13C variants showed reduced
expression in the prefrontal and temporal cortex as well as in the
hippocampus and cerebellum. Our genetic and expression data sug-
gested that the VPS13C non-synonymous variants contribute by a
loss-of-function mechanism similar to the effect of protein-truncating
variants. In addition, they underscored that the VPS13C variants affect
residues that are essential for protein function. Cellular expression
studies indicated co-localization with late endosomes and lysosomes, in
accordance with the subcellular distribution of VPS13C in the study
of Lesage et al. 2016. Additional functional studies are needed to
understand the contribution of VPS13C to LBD and PD.
References
1. Nalls MA, Pankratz N, Lill CM, Do CB, Hernandez DG, Saad M, et al.
Large-scale meta-analysis of genome-wide association data identifies six new risk loci
for Parkinson’s disease. Nat Genet 2014;46:989–993. doi: 10.1038/ng.3043
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VPS13D, a New Ataxia Gene, Plays an Essential Role
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Recent genetic studies in humans have associated mutations in VPS13D
with adult-onset ataxia. Using Drosophila melanogaster as a model system to
study the cellular functions of Vps13D in the nervous system, we
identified an essential role in the maintenance of mitochondrial structure.
Loss-of-function mutations in VPS13D lead to severe defects in mito-
chondrial morphology in multiple tissues, and early larval lethality.
Targeted knockdown of VPS13D in subsets of neurons and muscle cells
circumvents this early lethality to allow further analysis. In both neurons
and muscle cells we observed oversized, atypical mitochondria, some of
which contain mitochondrial inner-membrane proteins but lack matrix
proteins, and vice versa. The autophagy machinery appears to be strongly
engaged in muscle cells, suggesting that these atypical mitochondria
represent breakdown intermediates. Atypical mitochondria with a similar
appearance also accumulate in VPS13D-depleted neurons, and, strik-
ingly, in nearby glial cells. We are currently testing whether these atypical
mitochondria are transferred from neurons to glia.
VPS13D knockdown also leads to accumulations of poly-ubiquitin
aggregates in neurons and muscles. Because this phenotype was
recently described for mutations in VPS13 (orthologous to the A and C
family members),1 we have begun to examine whether Drosophila
VPS13-null mutants share mitochondrial defects with VPS13D, and
have noted preliminary similarities in certain tissues. Altogether, these
observations dovetail with findings for other VPS13 family members,
suggesting an important role in the maintenance of mitochondria.
Reference
1. Vonk JJ, Yeshaw WM, Pinto F, Faber AIE, Lahaye LL, Kanon B, et al.
Drosphila Vps13 is required for protein homeostasis in the brain. PLoS One 2017;12:
e0170106. doi: 10.1371/journal.pone.0170106
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Yeast Vps13p is the prototype of a family of conserved eukaryotic
proteins that includes four human homologs, VPS13A–D, each the
locus of an autosomal recessive neurodegenerative or neurodevelop-
mental disorder. Vps13p is involved in a variety of membrane trans-
actions (homotypic fusion, vesicular transport, prospore membrane
maturation) and also localizes to several membrane/organelle contact
sites (nuclear–vacuolar, mitochondrial–vacuolar, and ER–lipid droplet
junctions). Using cell-free fusion and transport assays, we found that
Vps13p is directly required for TGN homotypic fusion and TGN-to-
late endosome vesicular transport. Extracts from cells with loss-of-
function mutations in VPS13 are defective in these reactions; however,
activity is restored by adding Vps13p purified from yeast. Soluble,
purified Vps13p is monomeric and occurs in complex with the small
calmodulin-like protein, Cdc31p (yeast centrin). Cdc31p is required for
both cell-free reactions. Under reaction conditions, purified Vps13p
binds to yeast membranes in an ATP-stimulated fashion. Purified
Vps13p also binds specifically to synthetic liposomes doped with
phosphatidic acid (PA), and phosphorylated forms of phosphatidyl
inositol including PI(3)P, PI(4)P, and PI(4,5)P2. Conserved, recombi-
nant domains expressed in and purified from Escherichia coli exhibit
lipid-selective binding [N-domain, PA; Duf1162 domain, PI(3)P;
C-domain, PI(4,5)P2]. Analysis of TEM images of negatively stained
Vps13p indicates that this large protein (3,144 residues, 358 kDa) is
folded into a flexible, curved, compact rod (28 6 6 nm), with a loop at
one end, that possesses a circular opening ~6 nm in diameter. Human
VPS13A in red blood cells is in a complex with b-actin and b-adducin,
suggesting a role for VPS13A in actin organization.1 A possible
b-adducin-related protein in yeast, Bsp1p, known to be an actin-capping
protein, is required for both TGN late endosome transport and TGN
homotypic fusion. It is hoped that molecular analysis of core functions of
yeast Vps13p will help inform studies of the human disease homologs.
Parts of this abstract have been published in De M, et al. J Cell Biol
2017;216:425–439.
Funding: Supported by the Lakritz-Weinbaum Gift Fund and the Protein
Folding Disease Initiative at the University of Michigan Medical School.
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Using Yeast Vps13 Models of Chorea-acanthocytosis
to Isolate Genetic and Chemical Suppressors
P. Soczewka, D. Kolakowski, W. Rzepnikowska, M. Grabiec, K. Flis,
J. Kaminska, T. Zoladek
Institute of Biochemistry and Biophysics Polish Academy of Sciences, Warsaw, Poland
Defects in the expression and structure of all human VPS13 (hVPS13A–
D) genes are linked to multiple disorders such as neurodegeneration,
cancers, and diabetes. In particular, mutations in the hVPS13A gene
lead to a complex, rare neurodegenerative disease known as chorea-
acanthocytosis (ChAc). The roles of Vps13 proteins in specific molec-
ular processes are still unclear. Vps13 proteins are conserved in
eukaryotes; in recent years, a number of studies have taken advantage
of simple experimental models, such as yeast Saccharomyces cerevisiae,
to investigate the function of Vps13 proteins. One Vps13 protein in
yeast is involved in vacuolar protein transport and, like hVps13A,
participates in phospholipid metabolism. One of the mutations found
in ChAc patients causes a I2771R amino acid substitution in hVps13A
protein that affects its localization in skeletal muscle cells. To dissect
the mechanism of pathogenesis of I2771R, we created and analyzed a
yeast strain carrying the equivalent mutation. We show that, in yeast,
substitution I2749R causes dysfunction of Vps13 protein, which
results in impaired actin cytoskeleton organization, endocytosis and
vacuolar transport, as well as growth defect on media supplemented
with various chemicals. We also show that Vps13, like hVps13A, binds
actin, and that this ability is not disrupted in mutant vps13-I2749R.
Moreover, we show that Vps13 binds phospholipids, especially phos-
phatidylinositol 3-phosphate (PI3P), via its SHR_BD and APT1
domains and substitution I2749R in APT1 domain attenuates this
ability. To determine whether vps13D or vps13-I2749R defects could
be overcome, we screened the yeast genomic library for multicopy
suppressor genes that restore growth of mutant cells on tester plates.
Five multicopy suppressor genes were isolated, including RCN2, which
encodes the negative regulator of calcineurin phosphatase, and a
fragment of MYO3 encoding actin cytoskeleton protein, which binds
calmodulin. This indicates the connection between Vps13 function-
ing and calcium signaling and shows that the effects of deletion muta-
tion could be overcome by changing other cellular pathways. With this
knowledge, we screened the library of FDA-accepted drugs for those
that restore growth of the vps13D strain on tester plates. We identified
six hits, which have been analyzed further for specificity. Modeling
of ChAc in yeast may shed light on the pathological mechanisms
underlying the disease and may also serve as experimental platform for
drug testing.
Funding: This study is funded by the National Science Centre Poland (UMO-
2015/19/B/NZ3/01515) and is based upon work from COST Action BM1307
PROTEOSTASIS, supported by COST (European Cooperation in Science
and Technology).
Copyright: ’ 2018 Soczewka et al.
8
Bivalent Cation-dependent Phosphoinositide Binding
by the Chorein APT1 Domain
D. Kolakowski, T. Zoladek, J. Kaminska
Institute of Biochemistry and Biophysics Polish Academy of Sciences, Warsaw, Poland
VPS13A is human gene encoding chorein, whose physiological function
at the molecular level is poorly understood. Studies show chorein
involvement in actin cytoskeleton organization and phospholipid
metabolism. Defects in chorein cause the neurodegenerative disease
chorea-acanthocytosis. The large size of chorein makes functional
characterization a difficult task. To overcome this issue, single or
double domains of chorein need to be studied. Chorein and Vps13
protein from yeast (Vps13 hereafter) have an SHR-binding domain
(SHR_BD) and an adjacent APT1 domain. The function of these
domains is still unknown; however, previous studies by our team
have revealed that a double SHR_BD-APT1 domain from Vps13
binds phosphatidylinositol-3-phosphate (PI3P). In order to analyze the
evolutionary conservation of the chorein domains mentioned above,
chimeric proteins were tested for their ability to complement defects of
the vps13D mutant. Chimeric proteins consisted of Vps13 protein in
which single APT1 or double SHR_BD-APT1 domains were sub-
stituted for domains originating from chorein. Western blot analysis
demonstrated that chimeric proteins are expressed at sufficient levels
in yeast cells. The results of phenotypic analysis showed lack of com-
plementation for all chimeric proteins tested; hence, comparison
between APT1 domains from chorein and Vps13 was conducted.
Since APT1 from Vps13 binds PI3P, a protein–lipid overlay assay was
performed for APT1 from chorein. This analysis revealed that chorein
APT1 binds PI3P; however, it binds phosphatidylinositol-5-phosphate
(PI5P) with higher affinity. Phospholipid binding on a flat surface
differs from interaction within a membrane. Broader analysis of PI3P
binding using liposomes revealed that the chorein APT1 domain binds
PI3P in a bivalent cation-dependent manner. Altered specificity in phos-
pholipid binding of yeast and human APT1 domains may explain a
lack of complementation by chimeric Vps13 of vps13D phenotypes. This
supports the view that phosphoinositide binding via the APT1 domain is
essential for most Vps13 functions and is regulated by bivalent cations.
Further studies are required to find out whether PI5P binding by APT1 of
chorein is also regulated by bivalent cations.
Funding: This study is funded by the National Science Centre Poland
(UMO-2015/19/B/NZ3/01515) and is based upon work from COST Action
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Science and Technology).
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Functional Link between Vps13 and Myo3, Type I Myosin
J. Kaminska, P. Soczewka, T. Zoladek
Institute of Biochemistry and Biophysics Polish Academy of Sciences, Warsaw, Poland
Mutations in the human VPS13 family of genes cause several diseases.
In particular, mutations in the hVPS13A gene lead to chorea-acanthocytosis.
A number of studies have taken advantage of simple model organisms,
like yeast, to elucidate the mechanisms underlying diseases. One of the
most powerful methods using yeast is genetic screening for multicopy
suppressors. Such dosage suppression is a genetic interaction in which the
overexpression of one gene rescues a mutant phenotype of another.
Increasing the gene dosage provides a means of probing gene function,
as it tends to cause an increase in the corresponding gene product activity.
We used this type of screen to study Vps13 function. We identified,
among others, a fragment of the MYO3 gene that, when overexpressed,
restored growth of the vps13D mutant on tester plates. The MYO3 gene
encodes myosin implicated in the organization of actin cytoskeleton
and endocytosis. The identified fragment of Myo3 protein contains an
N-terminal motor head domain and a linker with IQ motifs responsible
for binding a negative regulator of Myo3: calmodulin (Cmd1). Substi-
tution of amino acids that disturb Myo3 fragment interaction with Cmd1,
as assayed in a two-hybrid system, resulted in the loss of ability of Myo3
to suppress the vps13D growth defect. Moreover, we found that over-
production of the Cmd1 variant, which is unable to bind Myo3, also
restores growth of vps13D. These results show that a defect of vps13D
could be overcome and point to a functional connection between Vps13,
Myo3, and calmodulin.
Funding: This study is funded by the National Science Centre Poland (UMO-
2015/19/B/NZ3/01515) and is based upon work from COST Action BM1307
PROTEOSTASIS, supported by COST (European Cooperation in Science
and Technology).
Copyright: ’ 2018 Kaminska et al.
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RCN2 Encoding the Calcineurin Regulator Is a Suppressor
of vps13 Mutations in a Yeast Chorea-acanthocytosis
Model
P. Soczewka, M. Grabiec, J. Kaminska, T. Zoladek
Institute of Biochemistry and Biophysics Polish Academy of Sciences, Warsaw, Poland
Chorea-acanthocytosis (ChAc) is a fatal, rare, genetic, neurodegen-
erative disease linked with mutations in the hVPS13A gene, one of four
VPS13 genes in humans. Mutations in hVPS13B and hVPS13C are also
implicated in human neurodegenerative disorders and an effective
cure for any of these diseases is lacking. VPS13 genes are conserved
from yeast to humans. Thus, yeast is a good model system to study
the function of Vps13 proteins, the effect of human mutations on
cell physiology, and to screen for suppressors of mutations in the
VPS13 gene. In yeast, there is one VPS13 gene and it is most homo-
logous to hVPS13A. The deletion of the VPS13 gene in yeast impairs
many functions such as intracellular trafficking, actin cytoskeleton
organization, and sporulation. A point mutation vps13-I2749R, which
mimics the point mutation found in ChAc patient, also exhibits loss-of-
function phenotypes. We identified the RCN2 gene as a multicopy sup-
pressor of vps13D, as well as the vps13-I2749R mutation. RCN2, next
to RCN1, encodes the regulator of calcineurin, a calcium- and calmodulin-
dependent protein phosphatase. Rcn1, depending on the expression level
and phosphorylation state, can stimulate and inhibit calcineurin; however,
Rcn2 shows only inhibitory activity when overexpressed. Here, we show
that overexpression of RCN2 diminishes sensitivity to canavanine and
improves actin cytoskeleton organization of vps13 mutant cells. Our
results suggest a possible link between calcium signaling and the function
of Vps13.
Funding: This study is funded by the National Science Centre Poland (UMO-
2015/19/B/NZ3/01515) and is based upon work from COST Action BM1307
PROTEOSTASIS, supported by COST (European Cooperation in Science
and Technology).
Copyright: ’ 2018 Soczewka et al.
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The Many Roles of VPS13 in Budding Yeast
J.-S. Park, A.M. Neiman
Department of Biochemistry and Cell Biology, Stony Brook University, Stony
Brook, NY, USA
The budding yeast Saccharomyces cerevisiae has a single VPS13 gene.
Mutation of VPS13 causes pleiotropic phenotypes. These phenotypes
implicate VPS13 in multiple cellular processes, including vesicular
traffic between the Golgi and endosome, mitochondrial maintenance,
sporulation, and others. Vps13 displays dynamic localization to mul-
tiple intracellular sites depending on growth conditions and alleles that
alter this distribution display subsets of the null phenotype, suggesting
that Vps13 activity at different subcellular sites contributes to its
multiple roles. Whether the different phenotypes of the null result from
loss of a single critical function or many different functions of the
protein is unclear. Genetic and cell biological studies suggest that
Vps13 may function at membrane contact sites, which are sites of
transfer of lipids and metabolites between organelles. We describe
evidence that VPS13 has a role in peroxisomal maintenance that is
related to membrane contact site function, and discuss the model
showing that the pleiotropic phenotypes of vps13 mutants are due to
multiple defects in membrane contact sites.
Copyright: ’ 2018 Park et al.
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Characterization of Human VPS13A-, VPS13C-, and
VPS13A and VPS13C double knockout cells
J.-S. Park, A.M. Neiman
Department of Biochemistry and Cell Biology, Stony Brook University, Stony
Brook, NY, USA
The human vacuolar protein sorting (VPS) 13 family consists of
four paralogs: VPS13A, VPS13B, VPS13C, and VPS13D. Muta-
tions in various VPS13 family genes are linked to multiple disorders
including neurodegeneration, neuronal diseases, diabetes, and
autism. In particular, genetic alterations in VPS13A and VPS13C
lead to a complex neuronal disorder chorea-acanthocytosis and
early-onset parkinsonism, respectively. The physiological roles of
the different VPS13 proteins, and whether they have distinct or over-
lapping cellular functions remains unknown. Eukaryotic VPS13
genes are evolutionarily highly conserved even in unicellular
budding yeast. Since yeast possesses a single VPS13 gene, studying
cellular functions of yeast VPS13 could help to understand the
basics of the human VPS13 family better. Several different bio-
logical roles of yeast VPS13 have been described: 1) differentiation
(sporulation), 2) endosomal vesicle traffic, and 3) mitochondrial
homeostasis. When disease-causing missense mutations in VPS13A
or VPS13C were characterized in yeast, VPS13 mitochondrial dys-
function was found to be a common phenotype, suggesting that this
may be the basis for the disease state in humans. To examine
whether VPS13A and VPS13C are important for mitochondrial
maintenance in human cells and to test for possible redundancy
between the human genes, we obtained human HAP1 cell lines in
which VPS13A, VP13C, or both VPS13A and VPS13C had been
inactivated using CRISPR. Our progress in characterizing these
cell lines will be discussed.
Copyright: ’ 2018 Park et al.
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The Role of VPS13A in the Endolysosomal and Autophagic
Pathways
S. Mun˜oz-Braceras, A. Tornero-e´cija, O. Vincent, R. Escalante
Instituto de Investigaciones Biome´dicas Alberto Sols, Madrid, Spain
VPS13 proteins are a group of conserved proteins whose mutations
lead to the appearance or elevated risk of various diseases. Particularly,
VPS13A mutations cause chorea-acanthocytosis, a rare neurodegen-
erative disorder, for which available treatments are not able to modify
disease progression. Human VPS13A and other members of the
VPS13 family have been implicated in autophagy and other cellular
processes; however, their molecular functions and the mechanistic
details of their participation in these processes are still unknown. We
propose that the function of VPS13 in autophagy is part of a more
general role in intracellular trafficking. This idea is supported by the
altered pattern of several proteins involved at distinct steps of vesicle-
dependent trafficking processes in human cells lacking VPS13A and
other findings in the simple model organism Dictyostelium discoideum.
Moreover, human and D. discoideum VPS13 proteins interact with a key
player in intracellular trafficking regulation. In addition, new avenues
to explore the exact role of VPS13 proteins in autophagy come from
elucidation of VPS13A subcellular localization. Altogether, our find-
ings provide the identification of potential targets that should be con-
sidered for the development of therapies for chorea-acanthocytosis.
Copyright: ’ 2018 Mun˜oz-Braceras et al.
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Drosophila Oogenesis as a Model System to Reveal Novel
Functions of Vps13
A.E. Faber, O.C.M. Sibon
Department of Cell Biology, University Medical Center Groningen, University
of Groningen, The Netherlands
Chorea-acanthocytosis (ChAc) is a rare neurodegenerative disease
characterized by progressive movement abnormalities and a spiked
form of red blood cell called acanthocytes. The disease is caused by
loss-of-function mutations in the VPS13A gene and in most cases leads
to the absence of the Vps13A protein. Knowledge of the underlying
pathophysiology of the disease and mechanisms involved is limited and
mainly based on studies in unicellular organisms or cultured cells. The
Drosophila melanogaster ovary system is widely used to study biological
and cellular processes because of its accessibility and the availability of
numerous genetic tools. Using CRISPR/Cas9, we created fly lines
harboring strong loss-of-function Vps13 (Vps13null) mutations to
further investigate the function and localization of Vps13. Vps13
protein is abundant in the Drosophila ovary, and analysis of mutant
ovaries showed the absence of Vps13 protein. In addition, mutant
females exhibit a striking deficit in egg laying and produce lower
numbers of offspring. Preliminary results revealed a higher number of
dying egg chambers in mutant ovaries. By further investigating the
ovary phenotype of Vps13 mutant females, we are attempting to gain
insights into the cellular processes in which Vps13 is involved.
Copyright: ’ 2018 Faber et al.
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A Mouse Model of Chorea-acanthocytosis
M. Nakamura, H. Sakimoto, O. Nagata, K. Arai, A. Sano
Department of Psychiatry, Kagoshima University Graduate School of Medical
and Dental Sciences, Kagoshima, Japan
Previously, we generated a mouse model of chorea-acanthocytosis
(ChAc-model mouse) that carries a targeted deletion mutation in the
mouse Vps13a gene corresponding to a human disease mutation. The
mutant mice, which have a hybrid C57BL/6J and a 129/Sv genetic
background, displayed variable phenotypes; this strongly suggested the
existence of modifier genes. Recently, we backcrossed the model mice
and created four strains carrying the Vps13a mutation on C57BL/6,
129/S6, Balb/c, and FVB genetic backgrounds. We investigated the
effects of the genetic background on the phenotypic variation of
ChAc-model mice using a number of behavioral analyses. ChAc-
model mice backcrossed to the various inbred strains exhibited
differences in symptoms. We suggest that this is a result of symptom-
modifying factors of ChAc in the genetic background. In this meeting,
we will review the ChAc-model mouse and recent findings on pheno-
types of epileptic seizure and male infertility.
Copyright: ’ 2018 Nakamura et al.
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The Phenotypic Variation in Chorea-acanthocytosis Model
Mice and the Search for Modifier Genes
K. Arai, H. Sakimoto, O. Nagata, M. Nakamura, A. Sano
Department of Psychiatry, Kagoshima University Graduate School of Medical
and Dental Sciences, Kagoshima, Japan
Previously, we constructed a ChAc mouse model encoding a human
disease mutation with deletion of exons 60–61 in the VPS13A gene.
The behavioral and pathological phenotypes of the model mice
showed strain differences. To establish the effect of the genetic back-
ground on phenotype, we produced ChAc-model mice on two dif-
ferent inbred strains: 129S6 and FVB. In ChAc-model mice on FVB,
hyperactivity in open field test and neurodegeneration in striatum was
observed. In ChAc-model mice on the 129S6, memory dysfunction in
the novel objects recognition test and neurodegeneration in the
hippocampus was observed. They also showed a decrease in prepulse
inhibition of startle response. Both strains showed motor dysfunction in
the balance beam test. These findings indicate that strain background
genes affect phenotype variation. Furthermore, we found that the
incidence of seizures in ChAc-model mice on 129S6 strain vary
according to pedigrees. We are now attempting to identify the genes
that modify seizure susceptibility.
Copyright: ’ 2018 Arai et al.
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1German Mouse Clinic, Institute of Experimental Genetics, Helmholtz Zentrum
Mu¨nchen, Munich, Germany, 2German Mouse Clinic, Institute of Develop-
mental Genetics, Helmholtz Zentrum Mu¨nchen, Munich, Germany, 3 Institute of
Molecular Animal Breeding and Biotechnology, Ludwig-Maximilians-Universita¨t
Mu¨nchen, Munich, Germany
The International Mouse Phenotyping Consortium (IMPC) pheno-
typically characterizes mouse knockout lines to identify genes involved
in disease development and progression, and to establish and offer mouse
models for human diseases to the scientific community. In humans,
mutations in genes of the VPS13 gene family may be associated with
several pathological phenotypes: VPS13A and VPS13C mutations have
been shown to cause neurological disorders and hematological altera-
tions, belonging to the so-called neuroacanthocytosis syndromes. VPS13B
mutations were associated with the rare Cohen syndrome, and genetic
alterations of VPS13D were found in cases of fetal death. Genome-wide
association studies (GWAS) also suggested an association of VPS13C
variants with certain types of cancer and type II diabetes. Three of the
four known members of this mammalian gene family were analyzed by
the IMPC: Vps13a, Vps13c, and Vps13d.
For the Vps13a gene, homozygous mutant young adult mice were
investigated at the age of 2–5 months. In addition to lower body weight
but higher relative body fat content, effects on bone metabolism and
reduced variability of red blood cell size were detected in these mice.
We characterized Vps13c mutant mice at an age of 2–5 months and,
in addition, after aging at an age of 12–15 months in the German
Mouse Clinic. Irrespective of age, homozygous mutant animals of this
line showed reduced body mass with reduced relative body fat content,
altered eye morphology including thinner retinas, chronic progressive
pancreatitis, and increased anisocytosis of erythrocytes. Aged mice also
showed further signs of altered energy metabolism, and mild
differences in behavioral and neurological tests. Vps13d-homozygous
mutations were lethal during early stages of embryonic development,
while heterozygous mutant mice showed no clear phenotype.
Our mouse models suggest novel pleiotropic effects of Vps13a and
Vps13c mutations that have not yet been described but may be relevant
for translation to human patients. A more detailed characterization of
pathogenic effects in the Vps13c mutant mouse line, especially regarding
eye morphology and vision, neurological consequences, and energy
metabolism, is currently under way at our institute. Further studies are
required to obtain a full picture of the pathologies associated with VPS13
gene mutations in humans and mice.
Copyright: ’ 2018 Rathkolb et al.
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Chorea-acanthocytosis – Characterization and Functional























1 Department of Neurology, University Hospital Carl Gustav Carus, Technische
Universita¨t Dresden, Dresden, Germany, 2DFG-Center for Regenerative
Therapies Dresden (CRTD), Technische Universita¨t Dresden, Dresden,
Germany, 3Department of Neurology, Hannover Medical School, Hanover,
Germany, 4 Department of Medicine, Section of Internal Medicine, University of
Verona, Policlinico GB Rossi, AOUI, Verona, Italy, 5 Institute of Neuroanatomy,
Hannover Medical School, Hanover, Germany, 6 Department of Neurology,
University of Rostock, Rostock, Germany, 7German Center for Neuro-
degenerative Diseases (DZNE) Rostock, Rostock, Germany, 8German Center
for Neurodegenerative Diseases (DZNE) Dresden, Dresden, Germany
Current address: *Zellkraftwerk GmbH, Leipzig, Germany, {AbbVie Deutschland
GmbH & Co KG, Neuroscience discovery, Ludwigshafen, Germany
Mutations in the VPS13A gene leading to depletion of chorein protein
are causative for chorea-acanthocytosis (ChAc), a movement disorder
characterized by red blood cell acanthocytes and degeneration of
striatal neurons, leading to epilepsy and hyperkinetic movement.
Recently, severe cell membrane disturbances based on dysregulation of
actin cytoskeleton caused by downregulation of the PI3K pathway and
hyperactivation of Lyn kinase were identified; however, to what extent
these mechanisms are present and relevant in the affected neurons
remains elusive. We studied the effect of chorein absence in GABAergic
medium spiny neurons derived from induced pluripotent stem cells of
ChAc patients. Morphology and trafficking of mitochondria and lyso-
somes is altered in ChAc patients. The number of both organelle types
is reduced and mitochondria are shortened, showing a hyperpolariza-
tion. In compartmentalized microfluidic chambers, a reduction in
retrograde transport was observed. Pharmacological interventions with
the Src kinase inhibitor PP2 were ineffective in treating the observed
phenotypes. Electrophysiological analysis revealed a significantly
elevated synaptic activity in ChAc. Treatment of cells with the actin
stabilizer phallacidin or PP2 resulted in the reduction of disinhibited
synaptic activity in ChAc neurons to the level in healthy controls,
suggesting an actin-dependent mechanism of pathologically enhanced
synaptic activity. These data suggest that the previously established
treatments of chorea-acanthocytosis-related phenotypes are not effec-
tive for all pathological deficiencies. The observed changes in lyso-
some and mitochondrial populations seem to act independent of the
electrophysiological phenotypes.
Copyright: ’ 2018 Glaß et al.
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Dopaminergic Neurons Derived from Chorea-acantho-
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Universita¨t, Dresden, Germany, 2CRTD, Center for Regenerative Therapies
Dresden, Technische Universita¨t, Dresden, Germany, 3DZNE, German Center
for Neurodegenerative Diseases, Rostock, Germany, 4Department of Neuro-
logy, University of Rostock, Rostock, Germany
Abstract: Mutations in the VPS13A gene encoding the protein chorein
cause chorea-acanthocytosis (ChAc), an autosomal recessive inherited
rare neurodegenerative disease. Patients suffer from a variety of symp-
toms: primarily a movement disorder with involuntary movements.
Although impairment in the cytoskeletal architecture in erythrocytes
and neurons of ChAc patients has been shown, the cause of neuronal
degeneration, however, remains not fully understood. As patients also
show parkinsonism, we used induced pluripotent stem cell (iPSC)-
derived human midbrain dopaminergic neurons (mDAN) from ChAc
patients and healthy donors and investigated them for in vitro pheno-
typic abnormalities.
Methods: Neural progenitor cells (NPCs) were derived from iPSCs
obtained by reprogramming skin fibroblasts of ChAc patients and
controls.1,2 NPCs were differentiated over the course of 30 days into
mDAN (2). Neuronal growth speed was evaluated using fluorescence
labeling of actin and measuring the cumulative length of all neurites,
number of branching points, and length of longest neurite at 24, 48,
and 72 hours after seeding. Survival of mDAN cultures upon stress
with rotenone and arsenite was quantified with the resazurin-based
PrestoBlueH assay and measurement of LDH levels in stressed cultures.
PrestoBlueH-measured viability activity was normalized to that of the
untreated control, and LDH levels were normalized to those of the
permeabilized untreated control.
Results: Neuronal growth of wild-type (WT) and ChAc mDAN at
defined time points after seeding was similar. The number of branch-
ing points, longest single neurite, and the number of neurites per
neuron did not differ either. Mature mDAN were stressed with rote-
none and arsenite at different concentrations. To assess their viability,
the PrestoBlueH assay was performed. Rotenone-treated mDANs from
ChAc patients showed significant lower cell viability at rotenone
concentrations of 100 and 200 nM. Arsenite-treated ChAc and WT
neurons displayed similar viability at arsenite concentrations of 5, 1,
and 0.2 mM. LDH levels were measured at 3 and 6 days. There was no
difference in the levels released by WT and ChAc neurons. When the
released LDH amount was normalized to the remaining cell viability
after stressing, there was no difference observed as well.
Conclusions: Midbrain dopaminergic neurons derived from healthy
donors and ChAc patients display similar neuronal growth in vitro.
mDAN derived from ChAc patients were significantly more vulnerable
than wild-type control neurons when complex 1 (NADH dehydrogenase)
NA Abstracts 2018: Cell Models doi: 10.7916/D8ZC9KCW
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of the mitochondrial respiratory chain was inhibited using rotenone.
This may indicate alterations of the respiratory chain, and thus of
ATP production, in midbrain dopaminergic neurons with VPS13A
mutations.
Funding: This work was supported by the Advocacy for Neuroacanthocytosis
patients and by the Federal Ministry of Education and Research (BMBF)
under the frame of E-Rare-2, the ERA-Net for Research on Rare Diseases
(FKZ 01GM1303).
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Disease-associated VPS13A Mutations: Consequences for
Neuronal Function and Survival
E. Tank, T. Qiao, A. Tidball, W. Dauer, J. Parent, S.J. Barmada
Department of Neurology, University of Michigan School of Medicine, Ann
Arbor, MI, USA
Mutations in the gene encoding vacuolar protein sorting 13 homo-
log A (VPS13A) are responsible for chorea-acanthocytosis (ChAc),
a neurodegenerative disorder characterized by seizures, cognitive decline,
involuntary dance-like movements of the limbs (chorea), and abnormal
red blood cell morphology. VPS13A participates in several essential
physiologic processes, including maintenance of cytoskeletal architecture,
protein turnover via autophagy, neurotransmitter release, and calcium-
mediated signaling. How disease-associated VPS13A mutations affect
such functions, and whether one or all of these activities are required
for neuronal survival, remains unknown. To answer these questions, we
pursued two complementary approaches. First, we developed a human
neuron model of ChAc by generating induced pluripotent stem cells
(iPSCs) from individuals with ChAc and unaffected family members, and
differentiating these into excitatory forebrain-like neurons. Second, we
utilized CRISPR/Cas9 genome editing to fluorescently label the VPS13A
protein at its endogenous locus in human cells, thereby obviating the need
for VPS13A-reactive antibodies and enabling non-invasive studies of
VPS13A localization and function in living cells. In ongoing studies,
we take advantage of a unique platform of automated microscopy with the
capacity to link disease-related phenotypes—such as altered neuronal
morphology, autophagy activity, protein clearance, and calcium home-
ostasis—to the probability of neuronal survival in a prospective fashion.
In this way, we will highlight the relevant pathways affected by pathogenic
VPS13A mutations, and emphasize therapeutic targets most likely to
effectively prevent neuron loss in ChAc and related neuroacanthocytosis
syndromes.
Copyright: ’ 2018 Tank et al.
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Disturbed Red Blood Cell Mechanics in Patients with
Neuroacanthocytosis
G. Bosman, D. Lazari, J. Freitas Leal, M. Adjobo-Hermans
Department of Biochemistry, Radboud University Medical Center, Nijmegen,
The Netherlands
The structure of red blood cells is affected by numerous inborn and
acquired factors; however, in most cases, this does not seem to affect
their function or survival in physiological conditions. Often, functional
deficits become apparent only when they are subjected to biochemical
or mechanical stress in vitro, or to pathological conditions in vivo.
Our in vitro data on the misshapen red blood cells of patients with neuro-
acanthocytosis suggest that abnormal red cell morphology is associated
with an increase in susceptibility to osmotic and mechanical stress, and
alters their rheological properties. We postulate that the underlying
mutations may not only affect these red cell functions, but may also
render neurons in specific brain areas more susceptible to a concomitant
reduction in oxygen supply. Through this mechanism, an increased sus-
ceptibility of compromised red blood cells to physiological stress con-
ditions may constitute an additional risk factor for vulnerable neurons.
Copyright: ’ 2018 Bosman et al.
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Mechanical Characterization of Blood Cells in Chorea-
acanthocytosis During Experimental Treatment with
Dasatinib or Lithium
F. Reichel, M. Kra¨ter, P. Rosendahl, M. Herbig, A. Rivera Prieto,
J. Guck
CMCB – TU, Dresden, Germany
The ability to deform and change shape is a vital feature of erythro-
cytes to withstand stresses as they pass through vessels just a fraction of
their own size. It is hypothesized that the mechanical parameters of red
blood cells (RBCs) change when they adopt the typical acanthocytic
phenotype. We demonstrate changes in deformability of healthy RBCs
and acanthocytes, as well as changes to these cells during experimental
chorea-acanthocytosis patient treatment with dasatinib or lithium,
by using three different microfluidic techniques. Our data provide
additional information to guide patient monitoring during treatment.
Copyright: ’ 2018 Reichel et al.
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Cellular Mechanisms Contributing to Acanthocytosis
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Chorea-acanthocytosis (ChAc), a neurodegenerative disease, results
from loss-of-function-mutations of the chorein-encoding gene VPS13A.
Affected patients suffer from a progressive movement disorder including
chorea, parkinsonism, dystonia, tongue protrusion, dysarthria, dyspha-
gia, tongue and lip biting, gait impairment, progressive distal muscle
wasting, weakness, epileptic seizures, cognitive impairment, and behav-
ioral changes. These pathologies may be paralleled by erythrocyte
acanthocytosis. Chorein supports activation of the phosphoinositide-
3-kinase (PI3K) p85 subunit with subsequent upregulation of
Ras-related C3 botulinum toxin substrate 1 (Rac1) activity, and
p21 protein-activated kinase 1 (PAK1) phosphorylation. Chorein-
sensitive PI3K signaling further leads to stimulation of the serum and
glucocorticoid inducible kinase SGK1, which in turn upregulates
ORAI1, a Ca2+ channel accomplishing store-operated Ca2+ entry
(SOCE). The signaling participates in the regulation of cytoskeletal
architecture on the one side and cell survival on the other. Compro-
mised cytoskeletal architecture has been shown in chorein-deficient
erythrocytes, fibroblasts, and endothelial cells. Impaired degranula-
tion was observed in chorein-deficient PC12 cells and in platelets
from ChAc patients. Similarly, decreased ORAI1 expression and
SOCE, as well as compromised cell survival, were seen in fibroblasts
and neurons isolated from ChAc patients. ORAI1 expression,
SOCE, and cell survival can be restored by lithium treatment, an
effect disrupted by pharmacological inhibition of SGK1 or ORAI1.
Chorein, SGK1, ORAI1, and SOCE further confer survival of tumor
cells. Additional examination is required exploring whether the in
vitro observations indeed reflect the in vivo pathology of the disease.
Copyright: ’ 2018 Lang et al.
24





1 Institute of Neuroanatomy and Cell Biology, Hannover Medical School, Hanover,
Germany, 2Center for Systems Neuroscience (ZSN) Hannover, Hanover,
Germany
Coordinated regulated of the actin cytoskeleton is an essential and
important process in diverse cell types. Actin dynamics comprises a
polymerization of monomeric, globular (G) actin into filamentous (F)
actin, and the depolymerization of F- into G-actin. These processes
are directly regulated by actin binding proteins: profilins bind to
G-actin and regulate its polymerization into F-actin and facilitates
G-actin recycling. Cofilin severs actin filaments into shorter ele-
ments thereby increasing the number of actin ends for increased
polymerization. Both proteins participate in the fine-tuned process
called actin treadmilling. Both profilin and cofilin are downstream
targets of Rho-kinase (ROCK). Therefore, ROCK is an important
signaling hub, and its dysregulation alters actin dynamics in multiple
cell types including neurons and glia. We have analyzed the roles
of profilin, cofilin, and ROCK in the motoneuron diseases spinal
muscular atrophy (SMA)1,2 and amyotrophic lateral sclerosis (ALS)3
as well as in chorea-acanthocytosis.4 We propose common mole-
cular mechanisms in SMA, and, for some cases, of ALS, based on
dysregulation of these signaling cascades resulting in altered actin
dynamics in these diseases.
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Chorea-acanthocytosis
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The two core neuroacanthocytosis syndromes, chorea-acanthocytosis
and McLeod syndrome, are progressive neurodegenerative disorders
that primarily affect the basal ganglia. The characteristic phenotype
comprises a variety of movement disorders, including chorea, dystonia,
and parkinsonism, and also psychiatric and cognitive symptoms attri-
butable to basal ganglia dysfunction. These disorders are managed
symptomatically and on a case-by-case basis, with very few practi-
tioners seeing more than a single case in their careers. There have been
no blinded, controlled trials, and only one retrospective case series of
patients undergoing deep brain stimulation for chorea-acanthocytosis.
The various therapies that have been used in the neuroacanthocytosis
syndromes will be summarized. Management remains at present
purely symptomatic, and thus is similar in principle to other more
common basal ganglia neurodegenerative disorders, such as Huntington’s
disease and Parkinson’s disease, in terms of treatment both the move-
ment disorders and the psychiatric issues. There are, in addition,
specific issues particular to these conditions that merit attention, such
as the early and prominent speech and swallowing issues in chorea-
acanthocytosis, and the cardiac and hematologic issues in McLeod
syndrome. An integrated multidisciplinary approach is the ideal
management strategy for these complex and multifaceted neuro-
degenerative disorders.
Copyright: ’ 2018 Walker
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Clinical, Genetic, and Biophysical Characterization of



























, N. C. Santos
1





1 Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa,
Lisbon, Portugal, 2Nu´cleo de Gene´tica Clı´nica, Departamento de Clı´nica Me´dica,
Hospital Universita´rio, UFSC, Floriano´polis, Brazil, 3 Servic¸o de Neurologia,
Departamento de Clı´nica Me´dica, Hospital Universita´rio, Universidade Federal
de Santa Catarina, Floriano´polis, Brazil, 4Department of Neurology, University
Hospital Alexandrovska, Sofia, Bulgaria, 5Great Ormond Street Hospital for Sick
Children, NHS Trust, London, UK, 6 Servic¸o de Medicina Fı´sica e de Reabilitac¸a˜o,
Hospital Da Senhora Da Oliveira, Guimaraes, Portugal, 7 Advocacy for
Neuroacanthocytosis Patients, London, UK, 8Neurologische Klinik, Ludwig-
Maximilians-Universita¨t, Munich, Germany, 9Department of Neurology, James J.
Peters VAMC, New York, NY, USA, 10Department of Neurology, Mount Sinai
School of Medicine, New York, NY, USA
Chorea-acanthocytosis (ChAc) is inherited in an autosomal recessive
manner. In 2012, we diagnosed, clinically and genetically, the only
known patient with ChAc in Portugal. Subsequently, with the help
of the Advocacy for Neuroacanthocytosis Patients, we genetically
analyzed cases from Brazil, Bulgaria, and the UK. Whenever
available, the diagnosis of ChAc was confirmed by chorein western
blot on red blood cell membranes.
Genetic analyses of the VPS13A gene supported the clinical diagnoses.
We found one splice site mutation (Brazilian case) one non-sense
(Bulgarian case), and three different frameshift mutations (Bulgarian
and UK cases) in total. Three of the mutations were novel. Inter-
estingly, the mutation detected in the Brazilian patient was different
from those described in another Brazilian case from the same city
(Floriano´polis).
We also analyzed the blood sample of our Portuguese patient for
changes of morphology and membrane elasticity of the red blood cells
compared with samples of seven healthy blood donors. Samples were
analyzed by atomic force microscopy (AFM), hemorheological
parameters, zeta-potential, and fluorescence generalized polarization.
The initial results demonstrated that the red blood cells of the ChAc
patient were softer than those of controls (255 ¡ 19 Pa vs. 553.8 ¡
35.6 Pa for the control; p , 0.0001) and have higher penetration
depth (1349¡ 17.4 nm vs. 811.3¡ 7.3 nm; p , 0.0001). Therefore,
red blood cells from the ChAc patient seem to be more capable of
deforming than those from the control group.
AFM scanning images of red blood cells from both groups revealed
that those from the ChAc patient were thicker than those of the
controls (0.714 ¡ 0.006 mm vs. 0.514 ¡ 0.004 mm; p , 0.0001);
further, the ChAc patient presented lower red blood cell membrane
roughness than the controls (p , 0.0001). Zeta-potential analysis did
not show significant changes on the electrical charge of the membranes.
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Fluorescence spectroscopy revealed that the RBC membranes of the
ChAc patient were more fluid.
Conclusions: The results of genetic analysis are useful for 1) con-
firmation of the clinical diagnosis, 2) obtaining data about mutation
frequency and disease prevalence, and 3) analysis of genotype-
phenotype associations in ChAc. AFM and other biophysical techni-
ques may be used for further elucidation of the physical characteristics of
acanthocytes. We offer our genetic and biophysical expertise for further
collaborations.
Copyright: ’ 2018 Lopes et al.
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Objective: To review the genetic causes of chorea documented to date in
Latin America and the Caribbean. Documentation of the presence of
these conditions will contribute to providing appropriate diagnostic
and clinical care.
Background: The increased availability of testing for Huntington’s
disease (HD) in previously resource-limited regions has revealed that
there are a number of patients with other rare conditions that result in
an HD-like phenotype.
Methods: The literature was surveyed for publications reporting a
variety of genetic choreic disorders, and in particular HD-like 2
(HDL2), chorea-acanthocytosis (ChAc), and McLeod syndrome
(MLS), in addition to the inherited ataxias. Movement disorders
specialists from countries in Latin America and the Caribbean were
contacted regarding their experiences with these disorders; they in turn
recommended other colleagues who might have informative experi-
ence in the area. Additional publications were identified from the local
literature. Contributions in Spanish and Portuguese were encouraged,
if appropriate.
Results: For HDL2, 27 cases were identified from 19 families from
Latin America. The majority were from Brazil, with others being
from Venezuela and Mexico. There were nine patients from three
families originating from the Caribbean. For ChAc, 32 patients from
18 families were identified from Latin America; there were five
patients from three families from Puerto Rico. For MLS, there were
25 patients from five families, the majority from two families from
Chile. The incidence of some of these disorders is likely determined
by factors such as variations in ethnic background and settlement
patterns; for example, HDL2 is particularly prevalent in regions or
countries where the population has African ancestry. Patients have also
been documented with chorea because of other conditions, such as the
inherited ataxias.
Conclusions: While rare, a significant number of patients affected by
the non-HD choreas are evidently present in Latin America and the
Caribbean. When not available locally, international collaborations
may facilitate diagnosis of rare genetic disorders. As genetic resources
and awareness of these disorders improve, more patients are likely to
be identified, with the potential to benefit from education, support,
and, ultimately, molecular therapies.
Copyright: ’ 2018 Walker et al.
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Objective: The aim was to document life expectancy and causes of
mortality in patients with chorea-acanthocytosis (ChAc) and McLeod
syndrome (MLS).
Background: ChAc and MLS are rare progressive neurodegenerative
conditions that cause a spectrum of neurological syndromes. There are
no data regarding life expectancy and causes of death. This infor-
mation would be valuable for disease management.
Methods: We reviewed our personal databases and the published litera-
ture to identify cases of ChAc and McLeod syndrome for whom
adequate information was available regarding age of disease onset, age
at death, cause of death, and clinical information such as presence of
seizures or cardiac disease.
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Results: Adequate information was obtained for 44 patients with ChAc
and 28 with McLeod syndrome. Causes of death included pneumonia,
cardiac disease, seizure, suicide, and sepsis. Mean disease duration for
ChAc was 11 years, while for McLeod syndrome it was 20 years.
Conclusions: Causes of death in ChAc and McLeod syndrome are
similar to those for the phenotypically similar Huntington’s disease,
with additional risks due to the presence of seizures and cardiac
disease. Suicidality was seen in 10% of patients with ChAc. In the
absence of disease-modifying agents, disease management should focus
upon treating symptoms that may contribute to morbidity.
Copyright: ’ 2018 Walker et al.
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Chorea-acanthocytosis (ChAc) is a rare hereditary neurodegenerative
disease caused by VPS13A deficiency leading to a spectrum of neuro-
logical symptoms and acanthocytosis of red blood cells. Furthermore,
male infertility has been reported in ChAc model mice in the past.
Herein, we present insights into the impairment of the male reproduc-
tive system in two ChAc patients showing asthenoteratozoospermia
and oligoasthenozoospermia, respectively, and in Vps13a-knockout
mice with similar abnormalities as evidenced by semen analysis. While
it is tempting to hypothesize that male infertility should be considered
as a new symptom complex associated with ChAc, studies with a
higher case number investigating fertility in male ChAc patients are
urgently needed to further address this question. Additionally, at the
pathophysiological level, the so-far unknown function of VPS13A in
spermatozoa and spermatogenesis remains to be revealed.
Copyright: ’ 2018 Peikert et al.
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Although the report of the extended New England family in the
1960s by Irving M. Levine and collaborators was seminal for the
development of the neuroacanthocytosis concept, a final diagnosis had
not been arrived at. We collated data on the individual members of
this family from the various, sometimes contradictory, reports. We
identified individual names and biographic dates in publicly available
archival material to redraw the pedigree in a modern fashion and to
properly place novel data in context that previously were only reported
in a meeting abstract or contained in patient charts of family members
seen at the National Institutes of Health.
The novel information presented here describes the long-term disease
course of six family members: all showed definite acanthocytosis in
their blood, and five of them (four siblings and the son of one sister)
developed findings suggestive of a neuroacanthocytosis syndrome, such
as chorea, seizures, cognitive impairment, hyporeflexia, or CK eleva-
tion. We regard their mothers neurological findings, however, as unrelated.
The reconstructed pedigree is incompatible with the autosomal reces-
sive transmission seen in chorea-acanthocytosis (OMIM #200150).
In addition, the respective ages of symptom manifestation, the absence
of feeding dystonia, and life duration of the patients would be atypical.
Despite some resemblance to rare pedigrees of X-linked McLeod
syndrome (OMIM #300842) where female mutation carriers had
manifested disease symptoms, this diagnosis appears unlikely as no
relevant heart disease was reported; in addition, one instance of male-
to-male transmission was observed.
In summary, we suggest that ‘‘Levine syndrome’’ might represent
another, as yet genetically unidentified, type of neuroacanthocytosis
that is transmitted as an autosomal-dominant trait. Unfortunately,
none of the tissue samples that had been collected could be recovered
for further, including molecular, analyses, and, so far, to our knowl-
edge, no descendants of the cases reported have been reassessed. Final
clarification of the status of the syndrome thus seems to depend on
serendipitous discoveries of members of the family that had first been
studied by Levine and collaborators more than half a century ago.
Past publications on the ‘‘Levine Family’’
1. Levine IM, Yettra M, Stefanini M. A hereditary neurological disorder
with acanthocytosis. Neurology 1960;10:425.
2. Kuo PT, Bassett DR. Blood and tissue lipids in a family with hypo-
beta-lipoproteinemia. Circulation 1962;26:660.
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3. Rovito DA, Pirone FJ. Acanthrocytosis associated with schizophrenia.
Am J Psychiatry 1963;120:182–185.
4. Levine IM. An hereditary neurological disease with acanthocytosis.
Neurology 1964;14:272.
5. Engel W, Levy RI, Watkins SP, Vroom FQ. Discussion. Trans Am Neurol
Assoc 1967;92:135–137.
6. Estes JW, Morley TJ, Levine IM, Emerson CP. A new hereditary
acanthocytosis syndrome. Am J Med 1967;42:868–881. doi: 10.1016/0002-
9343(67)90068-X
7. Levine IM, Estes JW, Looney JM. Hereditary neurological disease with
acanthocytosis, a new syndrome. Arch Neurol 1968;19:403–409. doi: 10.1001/
archneur.1968.00480040069007
8. Levine IM, Estes JW, Looney JM. An hereditary neurological disease with
acanthocytosis. Excerpta Medica Int Congr Ser 1969;175:813–821.
9. Scharre DW. Neuropsychiatric features of chorea-acanthocytosis. Neuro-
logy 1994;44:A334–A335.
Copyright: ’ 2018 Danek et al.
31
Chorea, Psychosis, Acanthocytosis, and Prolonged


























1Department of Neurology, Karolinska University Hospital, Stockholm, Sweden,
2Department of Clinical Neuroscience, Karolinska Institutet, Stockholm,
Sweden, 3Department of Medical Biochemistry and Biophysics, Karolinska
Institutet, Stockholm, Sweden, 4 Center for Inherited Metabolic Diseases,
Karolinska University Hospital, Stockholm, Sweden, 5Department of Neuro-
imaging, Karolinska Institutet, Stockholm, Sweden, 6Department of Laboratory
Medicine, Karolinska University Hospital, Stockholm, Sweden, 7 Department
of Nuclear Medicine, Karolinska University Hospital, Stockholm, Sweden,
8 Department of Neurology, James J. Peters Veterans Medical Affair Center,
New York, NY, USA, 9 Department of Neurology, Mount Sinai School of
Medicine, New York, NY, USA
*These authors contributed equally.
Introduction: ElaC ribonuclease 2 (ELAC2) has been identified as a
subunit of the RNaseZ complex that is associated with the processing
of mtDNA-encoded transcripts. Mutations in the ELAC2 gene are
associated with rare autosomal recessive mitochondrial disease, leading
to hypertrophic cardiomyopathy and usually death during childhood.
Movement disorders have not been described as part of the ELAC2-
associated disease spectrum.
Methods and results: Here, we described a 69-year-old Assyrian female
affected by huntingtonism, waddling gait, olfactory hallucinations, type
2 diabetes, and hearing loss requiring aids. Her motor features had
been slowly progressive. EMG revealed myopathy and a muscle biopsy
revealed COX-negative and red ragged fibers. Repeated blood smears
revealed acanthocytosis. Cognitive decline was also evident. MRI and
FDG-PET scan of the brain revealed widened perisylvian sulci and
reduced metabolism in these regions. Huntington’s disease (HD) and
other HD phenocopies were ruled out (pathological expansions of
c9orf72, SCA17, and HDL2, and mutations in the PRNP gene).
Further investigations via whole-exome sequencing revealed the
new trans variants c.394G>A and c.1040C>T in the ELAC2 gene.
Repeated echocardiography demonstrated mild ventricular septum
hypertrophy. We did not find any evidence of respiratory chain defect
in the muscle biopsy; however, molecular characterization of patient
fibroblasts revealed the accumulation of unprocessed mitochondrial
transcripts but normal steady-state levels of mitochondrial mRNAs
and tRNAs. Furthermore, patient fibroblasts showed severe growth
impairment when using galactose as energy source.
Discussion and conclusion: This is the first report of the association of
ELAC2 mutations with huntingtonism and long-term survival. Other
mitochondrial diseases associated with chorea include Leigh syndrome
and MELAS. One MELAS case has been reported to be associated
with acanthocytosis. Myopathy, hearing loss, diabetes, and polyneuro-
pathy are signs of mitochondrial disease but not HD. Myopathy and
polyneuropathy are manifestations of neuroacanthocytosis syndromes
(specifically chorea-acanthocytosis and McLeod syndrome (MLS)).
Dilated, but not hypertrophic, cardiomyopathy is typical of MLS. This
case illustrates that mutations in ELAC2 are not exclusively confined to
a lethal pediatric cardiomyopathy, but may have a presentation that
could be included under the neuroacanthocytosis syndromes.
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